阿达木单抗对日本银屑病关节炎患者中轴表现的影响:24周前瞻性观察研究
结果显示91%患者存在脊柱炎,全部患者有MRI证实的骶髂关节炎,24周阿达木单抗治疗改善了脊柱炎部位数和骶髂关节炎平均分级。
要点
- 银屑病关节炎患者中轴受累常见,MRI显示91%存在脊柱炎,全部有骶髂关节炎。
- 24周阿达木单抗治疗可改善脊柱炎部位数和骶髂关节炎平均分级。
- 骶髂关节炎右侧严重程度显著高于左侧(P < 0.05)。
核心结论
- 阿达木单抗治疗24周可改善银屑病关节炎患者的脊柱炎和骶髂关节炎。
主要发现
- 91%(n = 31)的银屑病关节炎患者至少一个部位MRI显示脊柱炎。
- 颈椎、胸椎和腰椎区域关节炎部位数分别为48、67和53。
- 全部患者有MRI确定的骶髂关节炎分级≥1,28例(82%)至少一个骶髂关节区域分级≥2。
- 骶髂关节炎右侧严重程度显著高于左侧(P < 0.05)。
- 34例患者中胸椎是最常见的脊柱炎部位。
关键数值与推荐
- 24周阿达木单抗治疗改善了平均脊柱炎部位数和平均骶髂关节炎分级。
临床怎么用
- 对银屑病关节炎患者应关注中轴受累,MRI可用于评估脊柱炎和骶髂关节炎。
- 阿达木单抗治疗24周可改善银屑病关节炎患者的中轴MRI表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: PsA is characterized by enthesitis, synovitis and osseous involvement in the peripheral and axial joints. Few studies have examined axial involvement in PsA using imaging techniques. Here we examined axial involvement in PsA patients using MRI. In addition, we determined the efficacy of 24 week adalimumab treatment in improving the MRI findings of spondylitis and sacroiliitis. METHODS: This was a prospective, open-label, single-arm study in patients with PsA. Adalimumab was administered to patients for a total of 24 weeks. MRI examinations were conducted at baseline and at week 24 of adalimumab treatment. RESULTS: Thirty-seven patients with PsA were included in this study. Spondylitis was observed in at least one site of the positive scan in 91% (n = 31) of patients with PsA. The number of arthritic sites in the cervical, thoracic and lumbar regions of the spine was 48, 67 and 53, respectively. All patients had MRI-determined sacroiliitis of grade ≥1 severity while 28 patients (82%) had grade ≥2 sacroiliitis in at least one sacroiliac region. Sacroiliac arthritis was statistically more severe on the right side than on the left side (P < 0.05). In 34 patients with PsA, the thoracic spine was the most common site of spondylitis. In addition, 24 week adalimumab treatment led to an improvement in the mean number of spondylitis sites and the mean grade of sacroiliitis. CONCLUSION: Treatment with adalimumab for 24 weeks resulted in improvement in spondylitis and sacroiliitis.
引用
- Makino T, Ihn H, Nakagawa M, et al. Effect of adalimumab on axial manifestations in Japanese patients with psoriatic arthritis: a 24 week prospective, observational study. Rheumatology (Oxford). 2021. PMID: 33394051. doi:10.1093/rheumatology/keaa829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。